Serum xylosyltransferase activity in diabetic patients as a possible marker of reduced proteoglycan biosynthesis

Diabetes Care

Volumn 31, Issue 10, 2008, Pages 2018-2019

  Götting, Christian ^a   Kuhn, Joachim ^a   Kleesiek, Knut ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; GLYCOSAMINOGLYCAN; PROTEOGLYCAN; TRANSFERASE; UNCLASSIFIED DRUG; XYLOSYLTRANSFERASE; GLYCOSYLATED HEMOGLOBIN; GLYCOSYLTRANSFERASE; UDP XYLOSE PROTEIN XYLOSYLTRANSFERASE; UDP XYLOSE-PROTEIN XYLOSYLTRANSFERASE;

ADULT; ARTICLE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; ENZYME ACTIVITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN FUNCTION; PROTEOGLYCAN SYNTHESIS; AGED; BIOSYNTHESIS; BLOOD; BLOOD DONOR; COHORT ANALYSIS; DIABETES MELLITUS; ENZYMOLOGY; METABOLISM; MIDDLE AGED; ONSET AGE; REFERENCE VALUE;

ADULT; AGE OF ONSET; AGED; BIOLOGICAL MARKERS; BLOOD DONORS; COHORT STUDIES; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; GLYCOSAMINOGLYCANS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MIDDLE AGED; PENTOSYLTRANSFERASES; PROTEOGLYCANS; REFERENCE VALUES;

EID: 56149106137     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-0909     Document Type: Article

References (13)

1. Vernier RL, Steffes MW, Sisson-Ross S. Mauer SM: Heparan sulfate proteoglycan in the glomerular basement membrane in type 1 diabetes mellitus. Kidney lnt 41: 1070-1080, 1992
2. Gotting C, Kuhn J, Kleesiek K: Human xylosyltransferases in health and disease. Cell Mol Life Sci 64:1498-1517, 2007
3. Yamagishi S, Imaizumi T: Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 11:2279-2299, 2005
4. Brownlee M: Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820, 2001
5. Jensen T: Pathogenesis of diabetic vascular disease: evidence for the role of reduced heparan sulfate proteoglycan. Diabetes 46 (Suppl. 2):S98-S100, 1997
6. Kjellen L, Bielefeld D, Hook M: Reduced sulfation of liver heparan sulfate in experimentally diabetic rats. Diabetes 32:337-342, 1983
7. Vogl-Willis CA, Edwards IJ: High-glucose-induced structural changes in the heparan sulfate proteoglycan, perlecan, of cultured human aortic endothelial cells. Biochim Biophys Acta 1672:36-45, 2004
8. Vogl-Willis CA, Edwards IJ: High glucose-induced alterations in subendothe-lial matrix perlecan leads to increased monocyte binding. Arterioscler Thromb Vasc Biol 24:858-863, 2004
9. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A: Albuminuria reflects widespread vascular damage: The Steno hypothesis. Diabetologia 32:219-226, 1989
10. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1. Diagnosis and classification of diabetes mellitus provisional report of aWHO consultation. Diabet Med 15:539-553, 1998
11. Kuhn J, Prante C, Schon S, Gotting C, Kleesiek K: Measurement of fibrosis marker xylosyltransferase I activity by HPLC electrospray ionization tandem mass spectrometry. Clin Chem 52:2243-2249, 2006
12. Gharagozlian S, Borrebaek J, Henriksen T, Omsland TK, Shegarfi H, Kolset SO: Effect of hyperglycemic condition on proteoglycan secretion in cultured human endothelial cells. Eur] Nutr 45:369-375. 2006
13. Schon S, Prante C, Bahr C, Kuhn J, Kleesiek K, Gotting C: Cloning and recombinant expression of active full-length xylosyltransferase I (XT-I) and characterization of subcellular localization of XT-I and XT-II. J Biol Chem 281: 14224-14231, 2006